Cited by 355Cannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsSchizophrenia research and treatment

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, AW, Crippa, Jas, Hallak, JEC, Pinto, JP, Chagas, MHN, Rodrigues, GGR, Dursun, SM, Tumas, V.·2009·Journal of Psychopharmacology

DOI 10.1177/0269881108096519

Open this paper in CoChat — free account

Abstract

The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.

Integrity signals

Registry

Crossref · 10.1177/0269881108096519

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder, C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 900
Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528
Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.
Bech, P., Kastrup, M., & Rafaelsen, O. J. (1986) · PubMed · Cited by 467
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 415
Self-citation

Show all 30 references

Research works printed but not linked: 7

Bech, P., 1986, Acta Psychiatr Scand Suppl, 326, 1
10.1111/j.1460-9568.1998.00292.x · DOI
Fahn, S., Elton, RL Members of the UPDRS Development Committee ( 1987) Unified Parkinson’s Disease Rating Scale (UPDRS) . In: Fahn, S, Marsden, CD, Calne, DB , Goldstein, M (eds), Recent Developments in Parkinson’s Disease, Vol. 2. Florahm Park, NJ: Macmillan Health Care Information , pp. 153-164.
First, MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-CV)
National Institute of Mental Health (1976) CGI - Clinical Global Impression. In: Guy, W (ed), ECDEU Assessment Manual of Psychopharmacology (revised) . Rockville, MD: NIMH, pp. 534- 537.
Zuardi, AW, 1994, Rev ABPAPAL, 16, 63
Zuardi, AW, 1995, J Clin Psychiatry, 56, 485

Sorted by citations

Items 201–300 of 354

Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor
Billard, É., Torbey, A. G., Inserra, A., Grant, E., Bertazzo, A., Gregorio, D. D., Comai, S., Chatenet, D., Gobbi, G., & Hébert, T. E. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111588 · Cited by 11
Rapid separation of cannabinoid isomer sets using differential mobility spectrometry and mass spectrometry
Mashmoushi, N., Campbell, J. L., Lorenzo, R. A. D., & Hopkins, W. S. (2022) · The Analyst · doi:10.1039/d1an02327f · Cited by 12
Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor (AhR)-dependent signaling
Jang, Y. S., Jeong, S., Kim, A., Mok, B. R., Son, S. J., Ryu, J.-S., Son, W. S., Yun, S. K., Kang, S., Kim, H. J., et al. (2023) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2023.01.008 · Cited by 12
Medical Cannabis in the Treatment of Parkinson’s Disease
Aladeen, T. S., Mattle, A. G., Zelen, K., Mesha, M., Rainka, M. M., Geist, T., Myers, B. A., & Mechtler, L. L. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000550 · Cited by 12
Cannabis, Cannabinoids, and the Association with Psychosis
Radhakrishnan, R., Addy, P. H., Sewell, R. A., Skosnik, P. D., Ranganathan, M., & D’Souza, D. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00014-9 · Cited by 12
Intraperitoneal cannabidiol attenuates neonatal germinal matrix hemorrhage-induced neuroinflamation and perilesional apoptosis
Almeida, T., Santos, M. V., Lopes, L. D. S., Goel, G., de Freitas, R. L., de Medeiros, P. S., Crippa, J. A. S., & Machado, H. R. (2019) · Neurological Research · doi:10.1080/01616412.2019.1651487 · Cited by 12
Self-citation
Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease
Urmeneta-Ortíz, M. F., Tejeda-Martínez, A. R., González‐Reynoso, O., & Flores-Soto, M. E. (2024) · Parkinson s Disease · doi:10.1155/2024/5519396 · Cited by 14
Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review
Völker, J. S. D., Micluția, I., & Vinași, R.-C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176821 · Cited by 14
Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo
Chu, P.-C., Liao, M.-H., Liu, M.-G., Li, C.-Z., & Lai, P. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455032 · Cited by 11
Cannabinoids in Parkinson’s disease
Concannon, R. M., Finn, D. P., & Dowd, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00003-5 · Cited by 11
Cannabis bei Parkinson – Hype oder Heilmittel?
Mainka, T., Stork, J., Hidding, U., & Buhmann, C. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-120668 · Cited by 11
Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial)
Mitarnun, W., Kanjanarangsichai, A., Junlaor, P., Kongngern, L., Mitarnun, W., Pangwong, W., & Nonghan, P. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107841 · Cited by 10
Cannabidiol zur Verbesserung der Genesung in frühen Stadien einer Schizophrenie
Rohleder, C., Müller, J. K., Hirjak, D., Meyer‐Lindenberg, A., & Leweke, F. M. (2018) · Nervenheilkunde · doi:10.1055/s-0038-1651941 · Cited by 9
Neuroprotective Effect of a Pharmaceutical Extract of Cannabis with High Content on CBD Against Rotenone in Primary Cerebellar Granule Cell Cultures and the Relevance of Formulations
Echeverry, C., Richeri, A., Fagetti, J., Martínez, G. F., Vignolo, F., Prunell, G., Cuñetti, L., Martínez-Busi, M., Pérez, S., de Medina, V. S., et al. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0289 · Cited by 9
The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions
Abbs, B., Achalia, R. M., Adelufosi, A. O., Aktener, A. Y., Beveridge, N. J., Bhakta, S. G., Blackman, R. K., Bora, E., Byun, M. S., Cabanis, M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.024 · Cited by 8
Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments
Rojas, M., Chávez-Castillo, M., Durán, P., Ortega, Á., Bautista-Sandoval, M. J., Salazar, J. J., Riaño-Garzón, M., Chacín, M., Medina, Ó., Palmar, J., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220428102802 · Cited by 11
Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases
Sharon, N., Yarmolinsky, L., Khalfin, B., Fleisher‐Berkovich, S., & Ben‐Shabat, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126402 · Cited by 9
Cannabidiol-enriched cannabis extraction product in Parkinson’s disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital
Kanjanarangsichai, A., Mitarnun, W., Mitarnun, W., Pangwong, W., Laoharattanahirun, N., Kajornrith, W., Junlaor, P., Nonghan, P., Witthayapirote, W., & Sangkarom, G. (2022) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp-2022-6-19 · Cited by 8
Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial
Dixon, T., & Cadenhead, K. S. (2023) · Trials · doi:10.1186/s13063-023-07789-w · Cited by 9
Cannabinoids for the Treatment of Movement Disorders
Catlow, B. J., & Sanchez‐Ramos, J. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0370-5 · Cited by 8
Cannabidiol and Neuroprotection: Evidence from Preclinical Studies
Schröder, N., da Silva, V. K., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00095-8 · Cited by 7
Self-citation
Cannabinoids, the Blood–Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives
Ben‐Shabat, S., Yarmolinsky, L., Sharon, N., Zeadnaa-Aldda, T., Dayan, S., Khalfin, B., & Fleisher‐Berkovich, S. (2026) · Biomolecules · doi:10.3390/biom16020225 · Cited by 7
Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects
Gupta, P., Singh, A., Shafi, S., Ralli, T., Pottoo, F. H., Sultana, Y., & Kohli, K. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230508142114 · Cited by 7
Mandatory pharmacist-led education session for patients seeking medical cannabis
Parihar, V., Katz, L., Siyam, M. A., Rogers, A., Patterson, L. L., & Zacharias, R. (2020) · Pharmacy Practice · doi:10.18549/pharmpract.2020.4.2088 · Cited by 7
Acceptability of cannabidiol in patients with psychosis
Chesney, E., Lamper, A. D., Lloyd, M., Oliver, D., Hird, E., & McGuire, P. K. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221128445 · Cited by 8
Pharmacological Interaction Between Cannabidiol and Tramadol on Experimental Diabetic Neuropathic Pain: An Isobolographic Analysis
Evans, A. A., Jesus, C. H. A., Martins, L. L., Fukuyama, A. H., Gasparin, A. T., Crippa, J. A. S., Zuardi, A. W., Hallak, J. E. C., Genaro, K., de Castro, C. J., et al. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0242 · Cited by 7
Self-citation
An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina
Fernández, N., Cappello, M. G., & Quiroga, P. N. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111762 · Cited by 7
The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases
Franco, G. R. R., & Viegas, C. (2017) · Revista Virtual de Química · doi:10.21577/1984-6835.20170103 · Cited by 7
The effects of Cannabis on hallucinations in Parkinson's disease patients
Brian, C., & Frei, K. P. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117206 · Cited by 7
Wirksamkeit von Cannabidiol: Klinische Studien mit Cannabidiol und Cannabidiol-haltigen Extrakten
Büechi, S. (2017) · Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine · doi:10.1159/000484886 · Cited by 7
uso do canabidiol (CBD) no tratamento da doença de Parkinson e suas comorbidades
SANTOS, R. G. D., Hallak, J. E. C., & Crippa, J. A. S. (2019) · Revista de Medicina · doi:10.11606/issn.1679-9836.v98i1p46-52 · Cited by 7
Self-citation
How Biodegradable Polymers Can be Effective Drug Delivery Systems for Cannabinoids? Prospectives and Challenges
Sobieraj, J., Strzelecka, K., Sobczak, M., & Olędzka, E. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s458907 · Cited by 7
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
Papakyriakopoulou, P., Valsami, G. N., & Ismailos, G. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70430 · Cited by 7
Can cannabidiol have an analgesic effect?
Kulesza, B., Mazurek, M., & Kurzepa, J. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12947 · Cited by 6
Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders
Morera‐Herreras, T., Miguélez, C., Aristieta, A., Torrecilla, M., Ruíz-Ortega, J. Á., & Ugedo, L. (2016) · InTech eBooks · doi:10.5772/62438 · Cited by 7
Repairing and Retrofitting Post-Tensioned Beams
Chakrabarti, P. R. (2005) · ACI Concrete International · Cited by 6
Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBP β protein synthesis in colorectal adenomas
Pan, J., Zhao, L., Du, H., Zhu, Y., Sun, X., Xu, Q., Cheng, H., Chen, H., & Sun, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013081 · Cited by 5
The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives
Baldasso, G. M., Paes, R. S., Moreira, A. F., Salvadori, S. G., Limberger, C., Roviezzo, F., Capasso, R., & Dutra, R. C. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108185 · Cited by 6
A journey through cannabidiol in Parkinson’s disease
Del-Bel, E., Barros, N., de Moraes, R. A. P. D. S., de Mattos, B. A., Alves-Fernandes, T. A., de Abreu, L. B., Nascimento, G. C., Escobar-Espinal, D. M., Pedrazzi, J. F. C., Jacob, G. A., et al. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.015 · Cited by 4
Can cannabidiol (CBD) help with low back pain?
Kulesza, B., Mazurek, M., & Kurzepa, J. (2023) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/168674 · Cited by 5
Permeation-Enhancing Strategies for Transdermal Delivery of Cannabinoids
Torabi, A., Madsen, F. B., & Skov, A. L. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0130 · Cited by 5
Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool
Kapler, S., Adery, L. H., Hoftman, G. D., Amir, C., Grigoryan, V., Cooper, Z. D., & Bearden, C. E. (2023) · Psychological Medicine · doi:10.1017/s0033291723002994 · Cited by 5
Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson’s Disease
Хаспеков, Л. Г., & Illarioshkin, S. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158520 · Cited by 5
Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation
Smith, S. L., Spurgeon, T., Spurgeon, R., & Heal, D. J. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00087 · Cited by 4
The Endocannabinoid System and Human Brain Functions
Ashton, J. C., Dowie, M. J., & Glass, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809666-6.00005-8 · Cited by 7
Accumulation of cannabidiol during the ontogenesis of industrial hemp
Міщенко, С. В., & Лайко, І. М. (2018) · Plant varieties studying and protection · doi:10.21498/2518-1017.14.4.2018.151902 · Cited by 6
Illinois Pharmacists and Over the Counter Cannabidiol Products: A Survey on Knowledge and Educational Needs
Link, K., Deshpande, M., & Ferguson, M. C. (2020) · INNOVATIONS in pharmacy · doi:10.24926/iip.v11i2.2968 · Cited by 5
CBD’s potential impact on Parkinson’s disease: An updated overview
Ghachi, H. E., Soulimani, R., Gamrani, H., & Kissani, N. (2024) · Open Medicine · doi:10.1515/med-2024-1075 · Cited by 7
Low doses of cannabis extract ameliorate non-motor symptoms of Parkinson’s disease patients: a case series
Ruver-Martins, A. C., Martínez, I., Holla, V. G., de Souza, B. L., da Silva, É. G., Aragón, D. M., Souza-Silva, E., de Araujo, F. S., Prediger, R. D., & do Nascimento, F. P. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1466438 · Cited by 4
A Review of Recent Advances in the Therapeutic Uses of Secondary Cannabinoids
Morabito, D. M., Soyster, P. D., Ramey-Wright, S., Belendiuk, K. A., & Bonn‐Miller, M. O. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0096-9 · Cited by 4
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial
Pessoa, R. M. D. P., Zuardi, A. W., Martins, R., Rodrigues, G. R., Hallak, J. E. C., Crippa, J. A. S., Pontes‐Neto, O. M., & Chagas, M. H. N. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251390974 · Cited by 3
Self-citation
Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review
Marques, B. L., Lirio, P. H. C., Vicente, M. A., Unzueta‐Larrinaga, P., Urigüen, L., & Campos, A. C. (2025) · Pharmaceuticals · doi:10.3390/ph18121817 · Cited by 3
The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder
Garel, N., Greenway, K. T., & Joober, R. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200114 · Cited by 3
Practical Recommendations for the Use of Medical Cannabis
Arboleda, M. F., & Prosk, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-69186-8_21 · Cited by 3
Recent developments in geriatric psychopharmacology
Aftab, A., Lam, J. A., Liu, F., Ghosh, A., & Sajatovic, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1882848 · Cited by 3
Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients
Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-30093-6_4 · Cited by 4
A nutraceutical role for cannabidiol. Why not?
Pierro, F. D. (2015) · Nutrafoods · doi:10.1007/s13749-015-0037-6 · Cited by 3
The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms
Jalali, S. (2013) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2013/6192 · Cited by 3
Cannabinoids in the Treatment of Parkinson’s Disease
Gandor, F., & Ebersbach, G. (2017) · Neurology International Open · doi:10.1055/s-0043-115359 · Cited by 3
Are cannabinoids effective for Parkinson’s disease?
Bravo‐Soto, G., & Carlos Juri, C. (2017) · Medwave · doi:10.5867/medwave.2017.6974 · Cited by 3
The potential role of cannabidiol (CBD) in lung cancer therapy: a systematic review of preclinical and clinical evidence
Esmaeli, M., & Dehabadi, M. D. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04010-7 · Cited by 1
Psychosis in Parkinson's Disease
Remz, M. A., & Salinas, M. R. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200210-02 · Cited by 2
Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis
Mielnik, C. A., Li, C. K., Ramsey, A. J., Salahpour, A., Burnham, W. M., & Ross, R. A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0125 · Cited by 2
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Peball, M., Heim, B., Carbone, F., Schorr, O., Werkmann, M., Ellmerer, P., Marini, K., Krismer, F., Knaus, H., Poewe, W. H., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00665-7 · Cited by 2
The Use of Cannabis-Based Medicine in Selected Neurological Disorders
Szejko, N., Saramak, K., & Müller‐Vahl, K. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_564 · Cited by 2
Cannabinoids in disorders of gut-brain interaction and gastrointestinal motility
Arboleda, M. F., Prosk, E., Watier, A., & Schmulson, M. J. (2021) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.20000021 · Cited by 2
Psychosis and Parkinson’s Disease
Vaughan, C. L., & Goldman, J. G. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-835-5_6 · Cited by 2
Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis
Hoch, E., Schneider, M., von Keller, R., Bonnet, U., Falkai, P., Hasan, A., Häuser, W., Hinz, B., Jakob, L., Kabisch, J., et al. (2018) · Springer eBooks · doi:10.1007/978-3-662-57291-7_4 · Cited by 2
Narrative Review of Cannabidiol as an Antipsychotic and Recommendations for Legal Regulations
Walkey, L. R. L., Tanguay, R. L., & el‐Guebaly, N. (2018) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000026 · Cited by 2
Box-Behnken Design Assisted Development and Optimization of RP-HPLC-PDA Technique for Determination of Cannabidiol in the Bulk and Nanoformulation
Ahmed, B., Usmani, Z., Rizwanullah, M., Mir, S. R., & Amin, S. (2021) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2021.82528.4072 · Cited by 2
Psychosis
Molho, E., & Factor, S. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-429-6_5 · Cited by 2
Cannabis Compounds: Potential Therapy for Neurological Disease
Babayeva, M., & Loewy, Z. G. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005770 · Cited by 1
Hope vs Hype III: Should physicians be more open in endorsing cannabis for Parkinson's disease?
Farbman, E. S., Anis, S., & Torres‐Russotto, D. R. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107811 · Cited by 1
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications
Okrah, E. A., Allan, C. Y., Doblin, M. S., & Annesley, S. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108943 · Cited by 2
Potential Therapeutic Strategy for Neurodegenerative Disorders: Insights from Natural Cannabis Compounds and Analogues
Tian, L., Zhang, B., Yang, X., Zhai, X., Gao, Y., Zhang, Y., Xie, X., Zhang, D., & Liang, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-95878-6_11 · Cited by 1
Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors
Burgaz, S., Rodríguez-Carreiro, S., Navarro, E., Lastres‐Becker, I., Garcı́a-Arencibia, M., Palomo‐Garo, C., Gómez‐Gálvez, Y., Gómez‐Cañas, M., García, C., & Fernández‐Ruíz, J. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00016-7 · Cited by 1
¿Media la dopamina los efectos psicóticos del Cannabis? Revisión e integración de los hallazgos a través de disciplinas
Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., & Henquet, C. (2012) · Psiquiatría Biológica · doi:10.1016/j.psiq.2012.09.005 · Cited by 1
Tratamiento de los trastornos psiquiátricos asociados al consumo de cannabis
Árias, F. (2011) · Trastornos Adictivos · doi:10.1016/s1575-0973(11)70024-1 · Cited by 1
Cannabidiol safety
Charrette, A., Akingbasote, J. A., Guthrie, N., & Hilmas, C. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821038-3.00039-2 · Cited by 1
Unveiling the therapeutic promise of medicinal cannabis protocol in alzheimer’s disease management: insights from case studies
Eichler, P. P. B. (2024) · MOJ Clinical & Medical Case Reports · doi:10.15406/mojcr.2024.14.00457 · Cited by 1
Advice to People with Parkinson’s in My Clinic: Cannabis
Freitas, M. E., & Fox, S. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230358 · Cited by 1
Cannabidiol: An Overview of its Antipsychotic Properties
Peres, F. F., de Almeida, V., & Abílio, V. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00092-2 · Cited by 1
Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders
Deiana, S., & Zamberletti, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00014-8 · Cited by 1
Pharmacotherapy of Psychosis in Parkinson’s Disease
Kwan, C., Frouni, I., & Huot, P. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_439-1 · Cited by 1
POSSIBILIDADES FUTURAS NA TERAPÊUTICA DE DIVERSAS PATOLOGIAS UTILIZANDO COMPOSTOS CANABINÓIDES
Oliveira, N. C., & de Bitencourt, R. M. (2021) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v7i5.1171 · Cited by 1
Pharmacotherapy of Psychosis in Parkinson’s Disease
Kwan, C., Frouni, I., & Huot, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_439 · Cited by 1
THERAPEUTIC POTENTIAL OF CANNABIDIOL: THE MOST IMPORTANT ACHIEVEMENTS ON THE WAY TO A NEW ERA
Shevchuk, M. M., & Volos, L. I. (2023) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2023.17 · Cited by 5
Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal
Nia, A. B., & Hurd, Y. L. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17121295 · Cited by 1
Avaliação do efeito neuroprotetor do canabidiol em mitocôndrias isolados de córtex cerebral de rato
Simões, A. C. V. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.60.2011.tde-29062011-202616
The acute effects of cannabinoids in patients with psychotic illness
Henquet, C., Sewell, A., Kuepper, R., Ranganathan, M., & D’Souza, D. C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511706080.019
P.1.g.048 Attenuation of haloperidol-induced extrapyramidal effects by cannabidiol administration in mice
Sonego, A. B., Gomes, F. V., Bel, E. A. D., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(14)70359-1
El dronabinol (THC) puede mejorar los síntomas de la esquizofrenia
Grotenhermen, F. (2009)
THC can improve symptoms of schizophrenia
Grotenhermen, F. (2009)
Role of the endocannabinoid system in human brain functions relevant for psychiatric disorders
Bossong, M. G. (2008) · Utrecht University Repository (Utrecht University)
THC kann Symptome der Schizophrenie verbessern
Grotenhermen, F. (2009)
Uso do Canabidiol como protetor contra disfunções cognitivas associadas ao acúmulo de ferro cerebral em ratos Wistar
Fagherazzi, E. V. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Tratamento repetido com canabidiol atenua alterações comportamentais e moleculares em um modelo de esquizofrenia baseado no antagonismo dos receptores NMDA
Gomes, F. V. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2016.tde-05012016-224242
Effectiveness of cannabidiol in reducing ketamine-induced schizophrenia-like behaviour in both male and female rats
Collins, M. A. (2011) · UC Research Repository (University of Canterbury) · doi:10.26021/8281
Subjecffve effects of cannabidiol in anxiety disorder and canabinoid excretion in chronic daily cannabis smokers during sustained abstinence
Bergamaschi, M. M. (2012) · doi:10.11606/t.60.2012.tde-11012013-102122
Interviewing and selecting staff: a team approach to interviewing.
Bowden, M., & Carbiener, A. O. (1978) · PubMed

Authors: Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V.
Affiliations: Universidade de São Paulo (BR)
Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
Corresponding author: Zuardi, AW
ORCID: Tumas, V.
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2008-09-18
Volume: 23
Issue: 8
Pages: 979-983
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881108096519
OpenAlex: W1967281437
Cited by: 355
References: 30
Citations by year: 2026: 14 · 2025: 15 · 2024: 28 · 2023: 34 · 2022: 28 · 2021: 33 · 2020: 39 · 2019: 29 · 2018: 21 · 2017: 20 · 2016: 17 · 2015: 12 · 2014: 14 · 2013: 8 · 2012: 9
FWCI: 7.24
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
Funders: Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
National Institutes of Health
National Institute of Mental Health
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: cannabidiol, Parkinson's disease, psychosis, antipsychotic drugs, neuroprotection, motor function, drug safety and tolerability, Brief Psychiatric Rating Scale
MeSH terms: Adult, Aged, Cannabidiol, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Psychotic Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabidiol for the treatment of psychosis in Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks